26 results on '"Sardesai, Niranjan Y."'
Search Results
2. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge
- Author
-
Patel, Vainav, Jalah, Rashmi, Kulkarni, Viraj, Valentin, Antonio, Rosati, Margherita, Alicea, Candido, von Gegerfelt, Agneta, Huang, Wensheng, Guan, Yongjun, Keele, Brandon F., Bess,, Julian W., Piatak,, Michael, Lifson, Jeffrey D., Williams, William T., Shen, Xiaoying, Tomaras, Georgia D., Amara, Rama R., Robinson, Harriet L., Johnson, Welkin, Broderick, Kate E., Sardesai, Niranjan Y., Venzon, David J., Hirsch, Vanessa M., Felber, Barbara K., and Pavlakis, George N.
- Published
- 2013
3. Plasmodium inui Infection Reduces the Efficacy of a Simian Immunodeficiency Virus DNA Vaccine in a Rhesus Macaque Model Through Alteration of the Vaccine-Induced Immune Response
- Author
-
Yin, Jiangmei, Vahey, Maryanne T., Dai, Anlan, Lewis, Mark G., Arango, Tatiana, Yalley-Ogunro, Jake, Greenhouse, Jack, Mendoza, Karla, Khan, Amir, Sardesai, Niranjan Y., Weiss, Walter, Komisar, Jack, and Boyer, Jean D.
- Published
- 2012
- Full Text
- View/download PDF
4. Multivalent Smallpox DNA Vaccine Delivered by Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox Challenge
- Author
-
Hirao, Lauren A., Draghia-Akli, Ruxandra, Prigge, Jonathan T., Yang, Maria, Satishchandran, Abhishek, Wu, Ling, Hammarlund, Erika, Khan, Amir S., Babas, Tahar, Rhodes, Lowrey, Silvera, Peter, Slifka, Mark, Sardesai, Niranjan Y., and Weiner, David B.
- Published
- 2011
- Full Text
- View/download PDF
5. Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
- Author
-
Tebas, Pablo, Kraynyak, Kimberly A, Patel, Ami, Maslow, Joel N, Morrow, Matthew P, Sylvester, Albert J, Knoblock, Dawson, Gillespie, Elisabeth, Amante, Dinah, Racine, Trina, McMullan, Trevor, Jeong, Moonsup, Roberts, Christine C, Park, Young K, Boyer, Jean, Broderick, Kate E, Kobinger, Gary P, Bagarazzi, Mark, Weiner, David B, and Sardesai, Niranjan Y
- Subjects
DNA vaccines ,HUMORAL immunity ,CLINICAL trial registries ,EBOLA virus ,VOLUNTEERS ,INTERLEUKIN-12 - Abstract
Background: Nonlive vaccine approaches that are simple to deliver and stable at room temperature or 2-8°C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. Using an immunopotent DNA vaccine that generates protection from lethal EBOV challenge in small animals and nonhuman primates, we performed a clinical study to evaluate both intramuscular (IM) and novel intradermal (ID) DNA delivery.Methods: Two DNA vaccine candidates (INO-4201 and INO-4202) targeting the EBOV glycoprotein (GP) were evaluated for safety, tolerability, and immunogenicity in a phase 1 clinical trial. The candidates were evaluated alone, together, or in combination with plasmid-encoded human cytokine interleukin-12 followed by in vivo electroporation using either the CELLECTRA® IM or ID delivery devices.Results: The safety profile of all 5 regimens was shown to be benign, with the ID route being better tolerated. Antibodies to EBOV GP were generated by all 5 regimens with the fastest and steepest rise observed in the ID group. Cellular immune responses were generated with every regimen.Conclusions: ID delivery of INO-4201 was well tolerated and resulted in 100% seroreactivity after 2 doses and elicited interferon-γ T-cell responses in over 70% of subjects, providing a new approach for EBOV prevention in diverse populations. Clinical Trials Registration. NCT02464670. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.
- Author
-
Muthumani, Karuppiah, Block, Peter, Flingai, Seleeke, Muruganantham, Nagarajan, Chaaithanya, Itta Krishna, Tingey, Colleen, Wise, Megan, Reuschel, Emma L., Chung, Christopher, Muthumani, Abirami, Sarangan, Gopalsamy, Srikanth, Padma, Khan, Amir S., Vijayachari, Paluru, Sardesai, Niranjan Y., Kim, J. Joseph, Ugen, Kenneth E., and Weiner, David B.
- Subjects
CHIKUNGUNYA virus ,PREVENTIVE medicine ,IMMUNOGLOBULINS ,DNA vaccines ,PLASMIDS - Abstract
Background: Vaccination and passive antibody therapies are critical for controlling infectious diseases. Passive antibody administration has limitations, including the necessity for purification and multiple injections for efficacy. Vaccination is associated with a lag phase before generation of immunity. Novel approaches reported here utilize the benefits of both methods for the rapid generation of effective immunity.Methods: A novel antibody-based prophylaxis/therapy entailing the electroporation-mediated delivery of synthetic DNA plasmids encoding biologically active anti-chikungunya virus (CHIKV) envelope monoclonal antibody (dMAb) was designed and evaluated for antiviral efficacy, as well as for the ability to overcome shortcomings inherent with conventional active vaccination and passive immunotherapy.Results: One intramuscular injection of dMAb produced antibodies in vivo more rapidly than active vaccination with an anti-CHIKV DNA vaccine. This dMAb neutralized diverse CHIKV clinical isolates and protected mice from viral challenge. Combination of dMAb and the CHIKV DNA vaccine afforded rapid and long-lived protection.Conclusions: A DNA-based dMAb strategy induced rapid protection against an emerging viral infection. This method can be combined with DNA vaccination as a novel strategy to provide both short- and long-term protection against this emerging infectious disease. These studies have implications for pathogen treatment and control strategies. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo.
- Author
-
Muthumani, Kar, Wise, Megan C., Broderick, Kate E., Hutnick, Natalie, Goodman, Jonathan, Flingai, Seleeke, Yan, Jian, Bian, Chaoran B., Mendoza, Janess, Tingey, Colleen, Wilson, Christine, Wojtak, Krzysztof, Sardesai, Niranjan Y., and Weiner, David B.
- Subjects
DNA vaccines ,PROTEINS ,T cells ,IMMUNE response ,HIV infections ,PHENOTYPES ,ELECTROPORATION ,IMMUNIZATION ,IMMUNOGENETICS - Abstract
An effective HIV vaccine will most likely require the induction of strong T-cell responses, broadly neutralizing antibodies (bNAbs), and the elicitation of antibody-dependent cellular cytotoxicity (ADCC). Previously, we demonstrated the induction of strong HIV/SIV cellular immune responses in macaques and humans using synthetic consensus DNA immunogens delivered via adaptive electroporation (EP). However, the ability of this improved DNA approach to prime for relevant antibody responses has not been previously studied. Here, we investigate the immunogenicity of consensus DNA constructs encoding gp140 sequences from HIV-1 subtypes A, B, C and D in a DNA prime-protein boost vaccine regimen. Mice and guinea pigs were primed with single- and multi-clade DNA via EP and boosted with recombinant gp120 protein. Sera were analyzed for gp120 binding and induction of neutralizing antibody activity. Immunization with recombinant Env protein alone induced low-titer binding antibodies with limited neutralization breath. In contrast, the synthetic DNA prime-protein boost protocol induced significantly higher antibody binding titers. Furthermore, sera from DNA prime-protein boost groups were able to neutralize a broader range of viruses in a panel of tier 1 clade B viruses as well as multiple tier 1 clade A and clade C viruses. Further investigation of synthetic DNA prime plus adaptive EP plus protein boost appears warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
8. HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice.
- Author
-
Kulkarni, Viraj, Rosati, Margherita, Valentin, Antonio, Ganneru, Brunda, Singh, Ashish K., Yan, Jian, Rolland, Morgane, Alicea, Candido, Beach, Rachel Kelly, Zhang, Gen-Mu, Le Gall, Sylvie, Broderick, Kate E., Sardesai, Niranjan Y., Heckerman, David, Mothe, Beatriz, Brander, Christian, Weiner, David B., Mullins, James I., Pavlakis, George N., and Felber, Barbara K.
- Subjects
THERAPEUTICS ,HIV infections ,DNA vaccines ,IMMUNE response ,LABORATORY mice ,BIODIVERSITY ,NUCLEOTIDE sequence ,VIRAL vaccines ,DRUG development - Abstract
Viral diversity is considered a major impediment to the development of an effective HIV-1 vaccine. Despite this diversity, certain protein segments are nearly invariant across the known HIV-1 Group M sequences. We developed immunogens based on the highly conserved elements from the p24
gag region according to two principles: the immunogen must (i) include strictly conserved elements of the virus that cannot mutate readily, and (ii) exclude both HIV regions capable of mutating without limiting virus viability, and also immunodominant epitopes located in variable regions. We engineered two HIV-1 p24gag DNA immunogens that express 7 highly Conserved Elements (CE) of 12–24 amino acids in length and differ by only 1 amino acid in each CE (‘toggle site’), together covering >99% of the HIV-1 Group M sequences. Altering intracellular trafficking of the immunogens changed protein localization, stability, and also the nature of elicited immune responses. Immunization of C57BL/6 mice with p55gag DNA induced poor, CD4+ mediated cellular responses, to only 2 of the 7 CE; in contrast, vaccination with p24CE DNA induced cross-clade reactive, robust T cell responses to 4 of the 7 CE. The responses were multifunctional and composed of both CD4+ and CD8+ T cells with mature cytotoxic phenotype. These findings provide a method to increase immune response to universally conserved Gag epitopes, using the p24CE immunogen. p24CE DNA vaccination induced humoral immune responses similar in magnitude to those induced by p55gag , which recognize the virus encoded p24gag protein. The inclusion of DNA immunogens composed of conserved elements is a promising vaccine strategy to induce broader immunity by CD4+ and CD8+ T cells to additional regions of Gag compared to vaccination with p55gag DNA, achieving maximal cross-clade reactive cellular and humoral responses. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
9. Electroporation delivery of DNA vaccines: prospects for success
- Author
-
Sardesai, Niranjan Y and Weiner, David B
- Subjects
- *
DNA vaccines , *ELECTROPORATION , *TECHNOLOGICAL innovations , *ANIMAL models in research , *IMMUNOREGULATION , *DRUG delivery systems - Abstract
A number of noteworthy technology advances in DNA vaccines research and development over the past few years have led to the resurgence of this field as a viable vaccine modality. Notably, these include – optimization of DNA constructs; development of new DNA manufacturing processes and formulations; augmentation of immune responses with novel encoded molecular adjuvants; and the improvement in new in vivo delivery strategies including electroporation (EP). Of these, EP mediated delivery has generated considerable enthusiasm and appears to have had a great impact in vaccine immunogenicity and efficacy by increasing antigen delivery upto a 1000 fold over naked DNA delivery alone. This increased delivery has resulted in an improved in vivo immune response magnitude as well as response rates relative to DNA delivery by direct injection alone. Indeed the immune responses and protection from pathogen challenge observed following DNA administration via EP in many cases are comparable or superior to other well studied vaccine platforms including viral vectors and live/attenuated/inactivated virus vaccines. Significantly, the early promise of EP delivery shown in numerous pre-clinical animal models of many different infectious diseases and cancer are now translating into equally enhanced immune responses in human clinical trials making the prospects for this vaccine approach to impact diverse disease targets tangible. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
10. A DNA Vaccine against Chikungunya Virus Is Protective in Mice and Induces Neutralizing Antibodies in Mice and Nonhuman Primates.
- Author
-
Mallilankaraman, Karthik, Shedlock, Devon J., Bao, Huihui, Kawalekar, Omkar U., Fagone, Paolo, Ramanathan, Aarthi A., Ferraro, Bernadette, Stabenow, Jennifer, Vijayachari, Paluru, Sundaram, Senthil G., Muruganandam, Nagarajan, Sarangan, Gopalsamy, Srikanth, Padma, Khan, Amir S., Lewis, Mark G., Kim, J. Joseph, Sardesai, Niranjan Y., Muthumani, Karuppiah, and Weiner, David B.
- Subjects
DNA vaccines ,HUMORAL immunity ,CHIKUNGUNYA virus ,PRIMATES ,CHIKUNGUNYA ,ARTIFICIAL chromosomes - Abstract
Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus indigenous to tropical Africa and Asia. Acute illness is characterized by fever, arthralgias, conjunctivitis, rash, and sometimes arthritis. Relatively little is known about the antigenic targets for immunity, and no licensed vaccines or therapeutics are currently available for the pathogen. While the Aedes aegypti mosquito is its primary vector, recent evidence suggests that other carriers can transmit CHIKV thus raising concerns about its spread outside of natural endemic areas to new countries including the U.S. and Europe. Considering the potential for pandemic spread, understanding the development of immunity is paramount to the development of effective counter measures against CHIKV. In this study, we isolated a new CHIKV virus from an acutely infected human patient and developed a defined viral challenge stock in mice that allowed us to study viral pathogenesis and develop a viral neutralization assay. We then constructed a synthetic DNA vaccine delivered by in vivo electroporation (EP) that expresses a component of the CHIKV envelope glycoprotein and used this model to evaluate its efficacy. Vaccination induced robust antigen-specific cellular and humoral immune responses, which individually were capable of providing protection against CHIKV challenge in mice. Furthermore, vaccine studies in rhesus macaques demonstrated induction of nAb responses, which mimicked those induced in convalescent human patient sera. These data suggest a protective role for nAb against CHIKV disease and support further study of envelope-based CHIKV DNA vaccines. Author Summary: Chikungunya fever epidemics are sustained by a cycle of human-mosquito-human transmission, with the epidemic cycle being similar to those of dengue and urban yellow fever. While the threat of a pandemic continues to engage the public's attention, the peculiar problems associated with the more immediate and very real seasonal epidemics are also worthy of consideration. Specifically, there are limited viral strains that have been characterized and available for laboratory study as well as limited knowledge of immune responses induced to the virus. In this study, we isolated CHIKV virus from an acutely infected human patient and used this new virus to develop a neutralization assay and a challenge stock, which is effective in a mouse model. Furthermore, we analyzed the ability of an envelope-based synthetic DNA-based vaccine to impact viral disease in the mouse model and to generate protective levels of immune responses in nonhuman primates. We observed that this novel vaccine approach generated protective levels of immune responses in both mouse and non-human primate models. We believe that these studies advance the field of Chikungunya vaccine research as well as the study of immune protection to CHIKV. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
11. Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP ® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults.
- Author
-
Edupuganti, Srilatha, C. De Rosa, Stephen, Elizaga, Marnie, Lu, Yiwen, Han, Xue, Huang, Yunda, Swann, Edith, Polakowski, Laura, A. Kalams, Spyros, Keefer, Michael, Maenza, Janine, C. Wise, Megan, Yan, Jian, Morrow, Matthew P., Khan, Amir S., Boyer, Jean D., Humeau, Laurent, White, Scott, Sardesai, Niranjan Y., and Bagarazzi, Mark L.
- Subjects
DNA vaccines ,ELECTROPORATION therapy ,ELECTROPORATION ,HIV status ,VISUAL analog scale ,ADULTS - Abstract
Background: Several techniques are under investigation to improve the immunogenicity of HIV-1 DNA vaccine candidates. DNA vaccines are advantageous due to their ease of design, expression of multiple antigens, and safety. Methods: The HVTN 098 trial assessed the PENNVAX
® -GP DNA vaccine (encoding HIV env, gag, pol) administered with or without plasmid IL-12 at 0-, 1-, 3-, and 6-month timepoints via intradermal (ID) or intramuscular (IM) electroporation (EP) in healthy, adult participants. We report on safety, tolerability, and acceptability. Results: HVTN 098 enrolled 94 participants: 85 received PENNVAX® -GP and nine received placebo. Visual analog scale (VAS) pain scores immediately after each vaccination were lower in the ID/EP than in the IM/EP group (medians 4.1–4.6 vs. 6–6.5, p < 0.01). IM/EP participants reported greater pain and/or tenderness at the injection site. Most ID/EP participants had skin lesions such as scabs/eschars, scars, and pigmentation changes, which resolved within 6 months in 51% of participants (24/55). Eighty-two percent of IM/EP and 92% of ID/EP participant survey responses showed acceptable levels of discomfort. Conclusions: ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. DNA Vaccine–Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination.
- Author
-
Hu, Xintao, Valentin, Antonio, Cai, Yanhui, Dayton, Frances, Rosati, Margherita, Ramírez-Salazar, Eric G., Kulkarni, Viraj, Broderick, Kate E., Sardesai, Niranjan Y., Wyatt, Linda S., Earl, Patricia L., Moss, Bernard, Mullins, James I., Pavlakis, George N., and Felber, Barbara K.
- Subjects
- *
DNA vaccines , *DRUG side effects , *CYTOTOXIC T cells , *HIV infections , *VACCINATION , *HLA histocompatibility antigens - Abstract
DNA-based vaccines able to induce efficient cytotoxic T-cell responses targeting conserved elements (CE) of human immunodeficiency virus type 1 (HIV-1) Gag have been developed. These CE were selected by stringent conservation, the ability to induce T-cell responses with broad human leukocyte antigen coverage, and the association between recognition of CE epitopes and viral control in HIV-infected individuals. Based on homology to HIV, a simian immunodeficiency virus p27gag CE DNA vaccine has also been developed. This study reports on the durability of the CE-specific T-cell responses induced by HIV and simian immunodeficiency virus CE DNA-based prime/boost vaccine regimens in rhesus macaques, and shows that the initially primed CE-specific T-cell responses were efficiently boosted by a single CE DNA vaccination after the long rest period (up to 2 years). In another cohort of animals, the study shows that a single inoculation with non-replicating recombinant Modified Vaccinia Ankara (rMVA62B) also potently boosted CE-specific responses after around 1.5 years of rest. Both CE DNA and rMVA62B booster vaccinations increased the magnitude and cytotoxicity of the CE-specific responses while maintaining the breadth of CE recognition. Env produced by rMVA62B did not negatively interfere with the recall of the Gag CE responses. rMVA62B could be beneficial to further boosting the immune response to Gag in humans. Vaccine regimens that employ CE DNA as a priming immunogen hold promise for application in HIV prevention and therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.
- Author
-
Smith, Trevor R.F., Schultheis, Katherine, Morrow, Matthew P., Kraynyak, Kimberly A., McCoy, Jay R., Yim, Kevin C., Muthumani, Karuppiah, Humeau, Laurent, Weiner, David B., Sardesai, Niranjan Y., and Broderick, Kate E.
- Subjects
- *
DNA vaccines , *RESPIRATORY syncytial virus infection vaccines , *DRUG delivery systems , *DRUG dosage , *DRUG development , *IMMUNE response - Abstract
Respiratory syncytial virus (RSV) is a massive medical burden in infants, children and the elderly worldwide, and an effective, safe RSV vaccine remains an unmet need. Here we assess a novel vaccination strategy based on the intradermal delivery of a SynCon® DNA-based vaccine encoding engineered RSV-F antigen using a surface electroporation device (SEP) to target epidermal cells, in clinically relevant experimental models. We demonstrate the ability of this strategy to elicit robust immune responses. Importantly we demonstrate complete resistance to pulmonary infection at a single low dose of vaccine in the cotton rat RSV/A challenge model. In contrast to the formalin-inactivated RSV (FI-RSV) vaccine, there was no enhanced lung inflammation upon virus challenge after DNA vaccination. In summary the data presented outline the pre-clinical development of a highly efficacious, tolerable and safe non-replicating vaccine delivery strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.
- Author
-
Yan, Jian, Villarreal, Daniel O., Racine, Trina, Chu, Jaemi S., Walters, Jewell N., Morrow, Matthew P., Khan, Amir S., Sardesai, Niranjan Y., Kim, J. Joseph, Kobinger, Gary P., and Weiner, David B.
- Subjects
- *
H7N9 Influenza , *INFLUENZA vaccines , *DNA vaccines , *IMMUNE response , *VIRAL envelope proteins , *HEMAGGLUTININ - Abstract
Abstract: Despite an intensive vaccine program influenza infections remain a major health problem, due to the viruses’ ability to change its envelope glycoprotein hemagglutinin (HA), through shift and drift, permitting influenza to escape protection induced by current vaccines or natural immunity. Recently a new variant, H7N9, has emerged in China causing global concern. First, there have been more than 130 laboratory-confirmed human infections resulting in an alarmingly high death rate (32.3%). Second, genetic changes found in H7N9 appear to be associated with enabling avian influenza viruses to spread more effectively in mammals, thus transmitting infections on a larger scale. Currently, no vaccines or drugs are effectively able to target H7N9. Here, we report the rapid development of a synthetic consensus DNA vaccine (pH7HA) to elicit potent protective immunity against the H7N9 viruses. We show that pH7HA induces broad antibody responses that bind to divergent HAs from multiple new members of the H7N9 family. These antibody responses result in high-titer HAI against H7N9. Simultaneously, this vaccine induces potent polyfunctional effector CD4 and CD8T cell memory responses. Animals vaccinated with pH7HA are completely protected from H7N9 virus infection and any morbidity associated with lethal challenge. This study establishes that this synthetic consensus DNA vaccine represents a new tool for targeting emerging infection, and more importantly, its design, testing and development into seed stock for vaccine production in a few days in the pandemic setting has significant implications for the rapid deployment of vaccines protecting against emerging infectious diseases. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
15. Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C.
- Author
-
Weiland, Ola, Ahlén, Gustaf, Diepolder, Helmut, Jung, Maria-Christina, Levander, Sepideh, Fons, Michael, Mathiesen, Iacob, Sardesai, Niranjan Y, Vahlne, Anders, Frelin, Lars, and Sällberg, Matti
- Subjects
- *
CHRONIC hepatitis C , *DNA vaccines , *ELECTROPORATION , *HEPATITIS C virus , *GENOTYPE-environment interaction - Abstract
Clearance of infections caused by the hepatitis C virus (HCV) correlates with HCV-specific T cell function. We therefore evaluated therapeutic vaccination in 12 patients with chronic HCV infection. Eight patients also underwent a subsequent standard-of-care (SOC) therapy with pegylated interferon (IFN) and ribavirin. The phase I/IIa clinical trial was performed in treatment naive HCV genotype 1 patients, receiving four monthly vaccinations in the deltoid muscles with 167, 500, or 1,500 μg codon-optimized HCV nonstructural (NS) 3/4A-expressing DNA vaccine delivered by in vivo electroporation (EP). Enrollment was done with 2 weeks interval between patients for safety reasons. Treatment was safe and well tolerated. The vaccinations significantly improved IFN-γ-producing responses to HCV NS3 during the first 6 weeks of therapy. Five patients experienced 2-10 weeks 0.6-2.4 log10 reduction in serum HCV RNA. Six out of eight patients starting SOC therapy within 1-30 months after the last vaccine dose were cured. This first-in-man therapeutic HCV DNA vaccine study with the vaccine delivered by in vivo EP shows transient effects in patients with chronic HCV genotype 1 infection. The interesting result noted after SOC therapy suggests that therapeutic vaccination can be explored in a combination with SOC treatment.Molecular Therapy (2013); 21 9, 1796-1805. doi:10.1038/mt.2013.119 [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model
- Author
-
Shen, Xuefei, Söderholm, Jonas, Lin, Feng, Kobinger, Gary, Bello, Alexander, Gregg, Derek A., Broderick, Kate E., and Sardesai, Niranjan Y.
- Subjects
- *
INFLUENZA vaccines , *ELECTROPORATION , *LABORATORY mice , *DNA vaccines , *ANTIBIOTICS , *PANDEMICS , *VIRAL antibodies , *VIRAL antigens - Abstract
Abstract: Alternative DNA vaccine constructs such as fully synthetic linear expressing cassettes (LECs) offer the advantage of accelerated manufacturing techniques as well as the lack of both antibiotic resistance genes and bacterial contaminants. The speed of manufacture makes LEC technology a possible future vaccination strategy for pandemic influenza outbreaks. Previously, we reported on a novel concept of DNA delivery to dermal tissue by a minimally invasive electroporation (EP) surface device powered using low voltage parameters. This device allows electroporation without penetration of electrodes into the skin. In addition to enhancing the delivery of traditional plasmid DNA vaccines, this device may also offer a safe, tolerable and efficient method to administer LECs. To assess immunogenicity and efficacy of EP-enhanced LEC delivery in mice, we designed and tested two influenza antigens in the form of LEC constructs delivered using the newly developed surface dermal EP device. Strong CTL and antibody responses were induced by the LEC versions of the DNA vaccine. When challenged with A/Canada/AB/RV1532/2009 viruses, mice immunized with LEC encoding the M2 and NP antigens recovered faster than naïve or mice immunized ID without EP. Mice immunized with equal-molar doses of LEC encoding the M2 and NP antigens demonstrated 100% survival following a lethal (100× LD50) challenge of the heterologuos and highly pathogenic H5N1 influenza virus (A/Vietnam/1203/04). These results suggest that influenza DNA vaccines based on LEC technology combined with the surface delivery platform are capable of fully protecting mice in a lethal challenge and the LEC based DNA constructs may serve as viable vaccine candidates. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
17. An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge
- Author
-
Hutnick, Natalie A., Myles, Devin J.F., Hirao, Lauren, Scott, Veronica L., Ferraro, Bernadette, Khan, Amir S., Lewis, Mark G., Miller, Christopher J., Bett, Andrew J., Casimiro, Danilo, Sardesai, Niranjan Y., Kim, J. Joseph, Shiver, John, and Weiner, David B.
- Subjects
- *
DNA vaccines , *HIV , *DRUG development , *DRUG dosage , *IMMUNE response , *CELLULAR immunity , *FLOW cytometry , *LABORATORY monkeys - Abstract
Abstract: One limitation in the development of an improved cellular response needed for an effective HIV-vaccine is the inability to induce robust effector T-cells capable of suppressing a heterologous challenge. To improve cellular immune responses, we examined the ability of an optimized DNA vaccine to boost the cellular immune responses induced by a highly immunogenic Ad5 prime. Five Chinese rhesus macaques received pVax encoding consensus (con) gag/pol/env intramuscularly (IM) with electroporation followed by the Merck Ad5 gag/pol/nef vaccine. A second group of five animals were vaccinated with Merck Ad5 gag/pol/nef followed by pVax gag/pol/env. One year following vaccination, Ad5-prime DNA-boosted monkeys and four unvaccinated controls received an intrarectal challenge with 1000 ID50 SIVmac251. The quality and magnitude of the T-cell response was analyzed by ELISpot and polyfunctional flow cytometry. We observed that an Ad5-prime DNA-boost resulted in significantly elevated SIV-specific T-cell responses even compared with animals receiving a DNA-prime Ad5-boost. Ad5 prime DNA boosted animals were capable of suppressing a pathogenic SIVmac251 challenge. Peak control correlated with the expansion of HLA-DR+ CD8+ T-cells two weeks post-infection. These data illustrate that high optimization of a DNA vaccine can drive of immune responses primed by a robust vector system. This previously unachievable feature of these newly optimized DNAs warrants future studies of this strategy that may circumvent issues of serology associated with viral vector prime–boost systems. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
18. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine
- Author
-
Yan, Jian, Corbitt, Natasha, Pankhong, Panyupa, Shin, Thomas, Khan, Amir, Sardesai, Niranjan Y., and Weiner, David B.
- Subjects
- *
IMMUNOGENETICS , *HIV , *DNA vaccines , *VIRUS isolation , *IMMUNE response , *CELLULAR immunity , *ELECTROPORATION , *NUCLEOTIDE sequence - Abstract
Abstract: DNA vaccines require significant engineering in order to generate strong CTL responses in both non-human primates and humans. In this study, we designed a clade C env gene (EY3E1-C) to decrease the genetic distances of virus isolates within clade C and focus the induced T cell responses to conserved clade C epitopes. After generating a consensus sequence by analyzing full-length clade C env early transmitter sequences, several modifications were performed to increase the expression of the EY3E1-C, including codon/RNA optimization, addition of Kozak sequence and addition of an IgE leader sequence. We also shortened the V1 and V2 loops to approximate early transmitter isolate sequences and the cytoplasmic tail was truncated to prevent envelope recycling. When studied as a DNA vaccine in Balb/c mice, compared to a primary codon-optimized clade C envelope DNA vaccine (p96ZM651gp140-CD5), this novel construct is up to three times more potent in driving CTL responses. Importantly this construct not only induces stronger cross-reactive cellular responses within clade C, it also induces stronger immune responses against clade B and group M envelope peptide pools than p96ZM651gp140-CD5. Epitope mapping demonstrated that EY3E1-C was able to induce clade C envelope-specific immune responses against 15 peptide pools, clade B envelope-specific immune responses against 19 peptide pools and group M envelope-specific immune responses against 16 peptide pools out of 29, respectively, indicating that a significant increase in the breadth of induced immune responses. The analysis of antibody responses suggested that vaccination of pEY3E1-C could induce a clade C envelope-specific antibody response. The cellular immune responses of pEY3E1-C could be further enhanced when the DNA was delivered by using electroporation (EP). Thus, the synthetic engineered consensus EY3E1-C gene is capable of eliciting stronger and broader CTL responses than primary clade C envelopes. This finding suggests that such synthetic immunogens could be important for examination of their potential as part of an efficient HIV DNA vaccine. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
19. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle
- Author
-
Lin, Feng, Shen, Xuefei, McCoy, Jay R., Mendoza, Janess M., Yan, Jian, Kemmerrer, Steve V., Khan, Amir S., Weiner, David B., Broderick, Kate E., and Sardesai, Niranjan Y.
- Subjects
- *
ELECTROPORATION , *DNA vaccines , *PROTOTYPES , *DRUG delivery systems , *SKIN care , *MUSCLES , *CELLULAR immunity , *NUCLEOPROTEINS - Abstract
Abstract: Electroporation (EP) of either muscle or skin has proven to be an efficient method for increasing DNA-based vaccine delivery and immunogenicity in small and large animals. Previous comparative studies in large animals suggest that intramuscular (i.m.) DNA EP delivery appears to favor cellular immunity, while intradermal (i.d.) EP delivery may favor humoral immunity. While current EP devices are primarily designed either for i.m. or i.d. delivery, we developed a novel prototype Dual-Depth Device (DDD) for EP-mediated simultaneous i.d. and i.m. delivery of DNA-based vaccines with an attempt to elicit superior antibody and cellular immune responses. We performed comparisons of DDD EP delivery with standard i.d. EP, standard i.m. EP, and combined delivery of i.d. and i.m. EP at separate sites, for the ability to induce antigen-specific immune responses. In a guinea pig model using a SynCon™ DNA vaccine encoding the influenza virus H5 hemaglutinin (H5HA), vaccination via DDD or combined delivery induced higher antibody titers than via either i.d. or i.m. delivery alone. In a mouse model using a DNA vaccine encoding the nucleoprotein (NP) of influenza H1N1, the resulting trend of antibody responses was similar to that detected in guinea pig study. Importantly, cellular immune responses in the DDD or combined delivery groups were significantly stronger than that in either i.d. or i.m. delivery groups. We conclude that EP-mediated DNA-based vaccine delivery to both skin and muscle is superior to delivery to either tissue alone for induction of antigen-specific antibody and cellular immunity. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
20. A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge
- Author
-
Shedlock, Devon J., Talbott, Kendra T., Cress, Christina, Ferraro, Bernadette, Tuyishme, Steven, Mallilankaraman, Karthik, Cisper, Neil J., Morrow, Matthew P., Wu, Stephan J., Kawalekar, Omkar U., Khan, Amir S., Sardesai, Niranjan Y., Muthumani, Karuppiah, Shen, Hao, and Weiner, David B.
- Subjects
- *
DNA vaccines , *LYMPHOCYTIC choriomeningitis virus , *VACCINATION , *ELECTROPORATION , *CELLULAR immunity , *IMMUNOGLOBULINS , *T cells , *DRUG administration - Abstract
Abstract: Protection against infection is the hallmark of immunity and the basis of effective vaccination. For a variety of reasons there is a great demand to develop new, safer and more effective vaccine platforms. In this regard, while ‘first-generation’ DNA vaccines were poorly immunogenic, new genetic ‘optimization’ strategies and the application of in vivo electroporation (EP) have dramatically boosted their potency. We developed a highly optimized plasmid DNA vaccine that expresses the lymphocytic choriomeningitis virus (LCMV) nucleocapsid protein (NP) and evaluated it using the LCMV challenge model, a gold standard for studying infection and immunity. When administered intramuscularly with EP, robust NP-specific cellular and humoral immune responses were elicited, the magnitudes of which approached those following acute LCMV infection. Furthermore, these responses were capable of providing 100% protection against a high-dose, normally lethal virus challenge. This is the first non-infectious vaccine conferring complete protective immunity up to 8 weeks after vaccination and demonstrates the potential of ‘next-generation’ DNA vaccines. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
21. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation
- Author
-
Yin, Jiangmei, Dai, Anlan, LeCureux, Jonathan, Arango, Tatiana, Kutzler, Michele A., Yan, Jian, Lewis, Mark G., Khan, Amir, Sardesai, Niranjan Y., Montefiore, David, Ruprecht, Ruth, Weiner, David B., and Boyer, Jean D.
- Subjects
- *
IMMUNOGLOBULINS , *HIV , *DNA vaccines , *DRUG delivery systems , *ELECTROPORATION , *IMMUNE response , *VIRAL replication - Abstract
Abstract: Background: Clade C is the predominant HIV-1 strain infecting people in sub-Saharan Africa, India, and China and there is a critical need for a vaccine targeted to these areas. In this study we tested a DNA based vaccine that encodes the SIVgag, SIVpol and HIV-1 envelope clade C. Methods: Rhesus macaques were immunized by electroporation with the DNA plasmid encoding optimized SIVgag, SIVpol and an HIV-1 env clade C with or without the adjuvant RANTES. Animals were monitored for immune responses and challenged following the final immunization with 25 animal infectious doses (AID) of SHIV-1157ipd3N4. Results: We found that the vaccine induced high levels of antigen specific IFN-γ producing effector cells and the capacity for CD4+ and CD8+ to proliferate upon antigen stimulation. Importantly, we found that the vaccine induced antibody titers as high as 1/4000. These antibodies were capable of neutralizing tier 1 HIV-1 viruses. Finally, when macaques were challenged with SHIV, viral loads were controlled in vaccinated groups. Conclusion: We conclude that immunization with a simian/human immunodeficiency virus DNA-based vaccine delivered by electroporation can induce cellular and humoral immune responses that are able to control viral replication. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
22. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques
- Author
-
Kulkarni, Viraj, Jalah, Rashmi, Ganneru, Brunda, Bergamaschi, Cristina, Alicea, Candido, von Gegerfelt, Agneta, Patel, Vainav, Zhang, Gen-Mu, Chowdhury, Bhabadeb, Broderick, Kate E., Sardesai, Niranjan Y., Valentin, Antonio, Rosati, Margherita, Felber, Barbara K., and Pavlakis, George N.
- Subjects
- *
IMMUNE response , *DNA vaccines , *ANTIGENS , *GENETIC vectors , *GENETIC regulation , *ENZYME regulation , *ELECTROPORATION , *LABORATORY mice - Abstract
Abstract: Optimized DNA vectors were constructed comprising the proteome of SIV including the structural, enzymatic, regulatory, and accessory proteins. In addition to native antigens as produced by the virus, fusion proteins and modified antigens with altered secretion, cellular localization and stability characteristics were generated. The DNA vectors were tested for expression upon transfection in human cells. In addition, the vectors were tested either alone or in combinations in mice and macaques, which provided an opportunity to compare immune responses in two animal models. DNA only immunization using intramuscular injection in the absence or presence of in vivo electroporation did not alter the phenotype of the induced T cell responses in mice. Although several fusion proteins induced immune responses to all the components of a polyprotein, we noted fusion proteins that abrogated immune response to some of the components. Since the expression levels of such fusion proteins were not affected, these data suggest that the immune recognition of certain components was altered by the fusion. Testing different DNA vectors in mice and macaques revealed that a combination of DNAs producing different forms of the same antigen generated more balanced immune responses, a desirable feature for an optimal AIDS vaccine. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
23. IL-28B/IFN-λ3 Drives Granzyme B Loading and Significantly Increases CTL Killing Activity in Macaques.
- Author
-
Morrow, Matthew P, Jian Yan, Pankhong, Panyupa, Shedlock, Devon J., Lewis, Mark G., Talbott, Kendra, Toporovski, Roberta, Khan, Amir S., Sardesai, Niranjan Y., and Weiner, David B.
- Subjects
- *
GENE therapy , *DNA vaccines , *INTERFERONS , *MACAQUES , *ANTINEOPLASTIC agents , *GENETIC translation , *ANIMAL models in research - Abstract
Type III/λ interferons (IFNs) were discovered less than a decade ago and are still in the process of being characterized. Although previous studies have focused on the function of IFN-λ3 (also known as interleukin (IL)-28B) in a small animal model, it is unknown whether these functions would translate to a larger, more relevant model. Thus in the present study, we have used DNA vaccination as a method of studying the influence of IFN-λ3 on adaptive immune responses in rhesus macaques. Results of our study show for the first time that IFN-λ3 has significant influence on antigen-specific CD8+ T-cell function, especially in regards to cytotoxicity. Peripheral CD8+ T cells from animals that were administered IFN-λ3 showed substantially increased cytotoxic responses as gauged by CD107a and granzyme B coexpression as well as perforin release. Moreover, CD8+ T cells isolated from the mesenteric lymph nodes (MLN) of animals receiving IFN-λ3 loaded significant amounts of granzyme B upon extended antigenic stimulation and induced significantly more granzyme B-mediated cell death of peptide pulsed targets. These data suggest that IFN-λ3 is a potent effector of the immune system with special emphasis on CD8+ T-cell killing functions which warrants further study as a possible immunoadjuvant. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
24. Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques.
- Author
-
Hirao, Lauren A., Ling Wu, Satishchandran, Abhishek, Khan, Amir S., Draghia-Akli, Ruxandra, Finnefrock, Adam C., Bett, Andrew J., Betts, Michael R., Casimiro, Danilo R., Sardesai, Niranjan Y., Kim, J. Joseph, Shiver, John W., and Weiner, David B.
- Subjects
- *
VACCINATION , *IMMUNE response , *DNA vaccines , *ELECTROPORATION , *MACAQUES , *ADENOVIRUS diseases , *SWINE influenza , *THERAPEUTICS - Abstract
DNA vaccines have undergone important enhancements in their design, formulation, and delivery process. Past literature supports that DNA vaccines are not as immunogenic in nonhuman primates as live vector systems. The most potent recombinant vector system for induction of cellular immune responses in macaques and humans is adenovirus serotype 5 (Ad5), an important benchmark for new vaccine development. Here, we performed a head-to-head evaluation of the Merck Ad5 SIV vaccine and an optimized electroporation (EP) delivered SIV DNA vaccine in macaques. Animals receiving the Ad5 vaccine were immunized three times, whereas the DNA-vaccinated animals were immunized up to four times based on optimized protocols. We observed significant differences in the quantity of IFNγ responses by enzyme-linked immunosorbent spot (ELISpot), greater proliferative capacity of CD8+ T cells, and increased polyfunctionality of both CD4+ and CD8+ T cells in the DNA-vaccinated group. Importantly, Ad5 immunizations failed to boost following the first immunization, whereas DNA responses were continually boosted with all four immunizations demonstrating a major advantage of these improved DNA vaccines. These optimized DNA vaccines induce very different immune phenotypes than traditional Ad5 vaccines, suggesting that they could play an important role in vaccine research and development. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. Development of a novel DNA SynCon™ tetravalent dengue vaccine that elicits immune responses against four serotypes
- Author
-
Ramanathan, Mathura P., Kuo, Yuan-Chia, Selling, Bernard H., Li, Qianjun, Sardesai, Niranjan Y., Kim, J. Joseph, and Weiner, David B.
- Subjects
- *
VIRAL vaccines , *DRUG development , *DENGUE hemorrhagic fever , *IMMUNE response , *SEROTYPES , *VIRUS diseases , *MOSQUITOES , *DISEASE exacerbation , *DNA vaccines - Abstract
Abstract: The increased transmission and geographic spread of dengue fever (DF) and its most severe presentations, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), make it one of the most important mosquito-borne viral disease of humans. Four distinct serotypes of dengue viruses are transmitted to humans through the bites of the mosquitoes. Currently there is no vaccine or antiviral drug against DV infections. Cross-protection between dengue virus serotypes is limited and antibody dependent enhancement (ADE) contributes significantly to the severity of the disease. The major challenge is to induce a broad durable immune response against all four serotypes of dengue virus simultaneously while avoiding the possible exacerbation of risk of developing the severe forms of disease through incomplete or modified responses. In order to address this worldwide concern, we present a synthetic consensus (SynCon™) human codon optimized DNA vaccine that elicits immunity against all four dengue serotypes. We cloned consensus DIII domain of E protein from all serotypes and expressed them as a single open reading frame in a mammalian expression vector, called pDV-U-DIII (dengue-vaccine universal). In mice, this dengue-universal construct elicits significant level of anti-DIII antibody that neutralizes all four dengue subtypes and prevents cell death induced by dengue infection. This is the first SynCon™ DNA vaccine that provides tetravalent immunity against all four serotypes of dengue virus. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
26. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII
- Author
-
Ramanathan, Mathura P., Kutzler, Michele A., Kuo, Yuan-Chia, Yan, Jian, Liu, Harrison, Shah, Vidhi, Bawa, Amrit, Selling, Bernard, Sardesai, Niranjan Y., Kim, J. Joseph, and Weiner, David B.
- Subjects
- *
INTERLEUKINS , *GENETIC engineering , *IMMUNOLOGICAL adjuvants , *WEST Nile virus , *JAPANESE B encephalitis , *PLASMIDS , *B cells , *DNA vaccines , *GENE expression , *VIRAL genetics , *FLAVIVIRUSES , *THERAPEUTICS - Abstract
Abstract: The Japanese encephalitis virus (JEV) and West Nile virus (WNV) are responsible for a large proportion of viral encephalitis in humans. Currently, there is no FDA approved specific treatment for either, though there are attempts to develop vaccines against both viruses. In this study, we proposed novel genetically engineered DNA vaccines against these two neurotrophic flaviviruses. The structural domain III (DIII) of E protein from these viruses is reported to carry dominant epitopes that induce neutralizing antibodies. Therefore we created consensus sequence of DIII domain across numerous strains of JEV and WNV. Based on the consensus amino acid sequence, synthetic codon and RNA optimized DIII-expressing DNA vaccine constructs with an efficient leader sequence were synthesized for immunization studies. In addition, we also constructed a genetically engineered IL15 DNA vaccine molecular adjuvant for co-stimulating the immune response against DIII clones. Vaccine constructs were delivered into BALB/C mice intramuscularly followed by electroporation using the CELLECTRA® in vivo electroporator. We have observed that the combined delivery of both WNV DIII and IL15-ECRO DNA vaccine constructs resulted in not only the highest level of antibody against DIII, but also enhanced cross reactivity with two other antigens tested. Also, coimmunization with IL15 plasmid further increased the immune response by four- to five-fold. Importantly, we have shown that IL15 coimmunization adjuvanted humoral responses against DIII antigens by elevating the level of antibody secreting B cells. Such a DNA vaccine approach may better help to control potential travel related infectious agents such as JEV. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.